A randomised phase II trial of capecitabine plus cisplatin vs S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment vs S-1 plus cisplatin randomised PII trial (XParTS II)
European Journal of Cancer Aug 23, 2018
Nishikawa K, et al. - In this phase II trial, experts compared capecitabine plus cisplatin (XP) with S-1 plus cisplatin (SP) in patients with advanced gastric cancer (AGC) to see if these regimens can be used as controls in a phase III study. They also explored whether histological subtypes favor XP or SP. Findings suggested a comparability of XP and SP, and these can be recommended as control arms in a phase III study for AGC. For the selection of XP or SP, histological subtypes were not sensitive markers.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries